A phase 1 open-label, safety, pharmacokinetic, and preliminary efficacy study of STRO-001, an anti-CD74 antibody drug conjugate, in patients with advanced B-cell malignancies.

被引：2
作者：
Krishnan, Amrita Y.
Shah, Nina
Spira, Alexander I.
Kaufman, Jonathan L.
Niesvizky, Ruben
Shah, Nirav Niranjan
Burke, John M.
Popplewell, Leslie
Martin, Thomas G.
Cheung, Julee
Matheny, Shannon L.
Leonard, John Paul
Molina, Arturo
机构：
[1] City Hope Natl Med Ctr, Duarte, CA USA
[2] Univ Calif San Francisco, San Francisco, CA 94143 USA
[3] Virginia Canc Specialists, Fairfax, VA USA
[4] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[5] New York Presbyterian Hosp, Cornell Campus, New York, NY USA
[6] Med Coll Wisconsin, Milwaukee, WI 53226 USA
[7] Rocky Mt Canc Ctr, Aurora, CO USA
[8] Sutro Biopharma, San Francisco, CA USA
[9] New York Presbyterian Hosp, Weill Cornell Med Coll, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.TPS7586
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS7586
引用
收藏
页数：1
相关论文
共 50 条
  • [21] An open-label, multicenter phase 1 study to characterize safety, tolerability, preliminary antitumor activity, pharmacokinetics, and pharmacodynamics of VIP943 monotherapy in patients with advanced CD123+hematologic malignancies.
    Strickland, Stephen Anthony
    Curran, Emily K.
    Jamy, Omer Hassan
    Percival, Mary-Elizabeth
    Johnson, Amy J.
    Birkett, Joseph
    Huang, Xin
    Frigault, Melanie M.
    Lerchen, Hans-Georg
    Stelte-Ludwig, Beatrix
    Navarro, Tasheda
    Peck, Jim
    Gross, Wyatt
    Izumi, Raquel
    Hamdy, Ahmed M.
    Daver, Naval Guastad
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [22] A Phase 1 Study of the Anti-CD37 Antibody-Drug Conjugate AGS67E in Advanced Lymphoid Malignancies. Interim Results
    Sawas, Ahmed
    Savage, Kerry J.
    Perez, Raymond
    Advani, Ranjana H.
    Butturini, Anna
    Lackey, Jacqueline
    Trave, Fabio
    Anand, Banmeet
    Huang, Yao
    Reyno, Leonard
    O'Connor, Owen A.
    BLOOD, 2015, 126 (23)
  • [23] Results of A Phase 1 Study of Milatuzumab, a Humanized Anti-CD74 Antibody, and Veltuzumab, a Humanized Anti-CD20 Antibody, In Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma
    Christian, Beth
    Alinari, Lapo
    Jones, Jeffrey A.
    Benson, Don M., Jr.
    Flynn, Joseph M.
    Porcu, Pierluigi
    Lustberg, Mark E.
    Phelps, Mitchell
    Poi, Ming
    Chung, Diana
    Quinion, Carl
    Byrd, John C.
    Wegener, William
    Goldenberg, David M.
    Baiocchi, Robert A.
    Blum, Kristie A.
    BLOOD, 2011, 118 (21) : 1584 - 1584
  • [24] A first-in-human, multicenter, open-label, phase 1 study of ATOR-1017, a 4-1BB antibody, in patients with advanced solid malignancies.
    Ullenhag, Gustav J.
    Yachnin, Jeffrey
    Carneiro, Ana
    Elison, Emma
    Carlsson, Malin
    Russell, Charlotte Astrid
    Smith, Karin Enell
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [25] A phase 2, open-label study of the combination of spartalizumab (PDR001) and LAG525 for patients with advanced solid tumors and hematologic malignancies.
    Piha-Paul, Sarina Anne
    Amin, Alpesh
    Kovacs, Christina
    Magley, Andrea
    Das Purkayastha, D.
    Zhuo, Ying
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [26] Pharmacokinetics, Safety, and Efficacy of Acalabrutinib in Chinese Patients with Relapsed/Refractory Mantle Cell Lymphoma and Other B-Cell Malignancies: An Open-Label, Multicenter Phase 1/2 Trial
    Zhu, Jun
    Song, Yuqin
    Li, Jianyong
    Zhou, Keshu
    Ke, Xiaoyan
    Cai, Zhen
    Zhang, Huilai
    Yao, Tingting
    Xia, Zhen
    Wang, Yiqiu
    Lai, Peiqiong
    Liu, Xiaofeng
    BLOOD, 2022, 140 : 6496 - 6497
  • [27] A Phase I Study of Milatuzumab, a Humanized Anti-CD74 Antibody, and Veltuzumab, a Humanized Anti-CD20 Antibody, In Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma
    Christian, Beth
    Alinari, Lapo
    Earl, Christian Tyler
    Wilding, Emily
    Quinion, Carl
    Lustberg, Mark
    Benson, Don M., Jr.
    Jones, Jeffrey A.
    Byrd, John C.
    Wegener, William A.
    Goldenberg, David M.
    Baiocchi, Robert A.
    Blum, Kristie A.
    BLOOD, 2010, 116 (21) : 1148 - 1149
  • [28] Phase I Open-Label Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Dilpacimab in Patients with Advanced Solid Tumors
    Gordon, Michael S.
    Nemunaitis, John
    Barve, Minal
    Wainberg, Zev A.
    Hamilton, Erika P.
    Ramanathan, Ramesh K.
    Sledge, George W., Jr.
    Yue, Huibin
    Morgan-Lappe, Susan E.
    Blaney, Martha
    Kasichayanula, Sreeneeranj
    Motwani, Monica
    Wang, Lan
    Naumovski, Louie
    Strickler, John H.
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (10) : 1988 - 1995
  • [29] A phase 1, open-label, randomized drug-drug interaction study of zanubrutinib with moderate or strong CYP3A inhibitors in patients with B-cell malignancies
    Tariq, Bilal
    Ou, Ying C.
    Stern, Jennifer C.
    Mundra, Vaibhav
    Doo, Nicole Wong
    Walker, Patricia
    Lewis, Katharine L.
    Lin, Chester
    Novotny, William
    Sahasranaman, Srikumar
    Opat, Stephen
    LEUKEMIA & LYMPHOMA, 2023, 64 (02) : 329 - 338
  • [30] A phase 1/2 open-label study of KY1044, an anti-ICOS antibody with dual mechanism of action, as single agent and in combination with atezolizumab, in adult patients with advanced malignancies.
    Patel, Manish R.
    Naing, Aung
    Burris, Howard A., III
    Lin, Chia-Chi
    Curigliano, Giuseppe
    Thistlethwaite, Fiona
    Minchom, Anna Rachel
    Ascierto, Paolo Antonio
    De Braud, Filippo G.
    Cecchini, Michael
    Hanekom, Wouter
    Sainson, Richard C. A.
    Wilson, Rosamund J.
    Quaratino, Sonia
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345